PD1 Expression in EGFRvIII-Directed CAR T Cell Infusion Product for Glioblastoma Is Associated with Clinical Response

The epidermal growth factor receptor variant III (EGFRvIII) has been investigated as a therapeutic target for chimeric antigen receptor (CAR) T cell therapy in glioblastoma. Earlier research demonstrated that phenotypic and genotypic characteristics in T cells and CAR T product predicted therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Oliver Y., Tian, Lifeng, Yoder, Todd, Xu, Rong, Kulikovskaya, Irina, Gupta, Minnal, Melenhorst, Jan Joseph, Lacey, Simon F., O’Rourke, Donald M., Binder, Zev A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120664/
https://www.ncbi.nlm.nih.gov/pubmed/35603165
http://dx.doi.org/10.3389/fimmu.2022.872756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120664/
https://www.ncbi.nlm.nih.gov/pubmed/35603165
http://dx.doi.org/10.3389/fimmu.2022.872756

Ejemplares similares